Cardiac myosin inhibitor is safe and effective in HCM in phase 2 trial
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
- ESC Heart Failure 2023Benefits of rapid uptitration of HF medications independent of baseline renal function
Jozine ter Maaten, MD, PhD
- ESC Heart Failure 2023Remote hemodynamic monitoring improves quality of life and reduces HF hospitalizations in HF
Jasper Brugts, MD, PhD
- ESC Heart Failure 2023Persistent benefit with RNAi targeting TTR in patients with ATTR cardiac amyloidosis
Marianna Fontana, MD, PhD
- ESC Heart Failure 2023ARNI superior to ARB in reducing NT-proBNP in patients with HFmrEF/HFpEF
Robert Mentz, MD